The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Open accessAbstract
BACKGROUND: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established. OBJECTIVE: To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain. DESIGN: Cross-sectional study to correlate levels of CSF Abeta42, total tau, and phosphorylated tau protein with neuropathologic changes in the brain. SETTING: Academic research. Patients The study included 123 patients (79 with clinically diagnosed AD, 29 with other dementia, and 15 with other neurologic disease). All underwent clinical evaluation and provided antemortem lumbar CSF samples, and neuropathologic data were collected from September 11, 1990, to March 13, 2003, in the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland. MAIN OUTCOME MEASURES: Levels of CSF Abeta42, total tau, and phosphorylated tau protein were measured using standard commercial immunoassays. Neuropathologic evaluations included the classic silver impregnation method and immunohistochemistry for Abeta, hyperphosphorylated tau, and alpha-synuclein. RESULTS: Cerebrospinal fluid Abeta42 and tau protein levels were related to amyloid load and the presence of neurofibrillary pathologic abnormalities in the brain. Cerebrospinal fluid Abeta42 level correlated inversely with total Abeta load in the brain, and CSF tau level correlated with results of immunohistochemistry for hyperphosphorylated tau and with the presence of neocortical neurofibrillary tangles. In multivariate logistic regression analysis, the number of neuritic plaques in the brain remained a significant predictor of decreased CSF Abeta42 level and of increased CSF tau level. Based on the ratio of phosphorylated tau level to Abeta42 level, sensitivity was 91.6%, and specificity was 85.7%, with an overall accuracy of 90.2% for the presence of pathologic neuritic plaque in the brain. CONCLUSIONS: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A characteristic biomarker profile, defined by reduced levels of Aβ42 in conjunction with elevated t-tau and p-tau, provides a robust biochemical signature for detecting AD pathology and distinguishing it from other neurodegenerative disorders72,73.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Cited by
Sorted by citations
Items 701–800 of 895
CSF biomarkers of neurotoxicity in childhood cancer survivors after cranial radiotherapy or surgery
Fernström, E., Jarfelt, M., Blomstrand, M., Lannering, B., Axelsson, M., Wasling, P., Björk‐Eriksson, T., Zetterberg, H., & Kalm, M. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52152 · Cited by 2
Biomarkers in Alzheimer’s Disease—Perspectives for the Future
Cummings, J. L. (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.01.23 · Cited by 2
Prevalence of cerebrospinal fluid Alzheimer disease-like pattern in atypical dementias
Padovani, A., Benussi, A., Ferrari, F., Archetti, S., & Borroni, B. (2012) · Advances in Alzheimer s Disease · doi:10.4236/aad.2012.13006 · Cited by 2
The Pattern of Cortical Lesions in Preclinical Stages
Braak, H., & Tredici, K. D. (2014) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-12679-1_7 · Cited by 3
Clinical Meaningfulness of Biomarker Endpoints in Alzheimer’s Disease Research
Ng, K. P., Pascoal, T. A., Li, X., Rosa‐Neto, P., & Gauthier, S. G. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_16 · Cited by 2
Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 2
Review of Treatment for Late-Life Depression
Hay, K., Stageman, W., & Allan, C. L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.021 · Cited by 2
Le piège de la maladie d'Alzheimer à présentation dysexécutive
Poujois, A., Perret‐Liaudet, A., & Thomas-Antérion, C. (2010) · Revue de neuropsychologie · doi:10.3917/rne.025.0028 · Cited by 2
Frontal EEG alterations induced by hippocampal amyloid pathology in rats
Hidişoğlu, E., & Chiantia, G. (2023) · Advances in Medical Sciences · doi:10.1016/j.advms.2023.09.006 · Cited by 2
Wyzwania terapii otępienia w chorobie Alzheimera
Gabryelewicz, T., & Mandecka, M. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Alzheimer’s Disease and Other Neurodegenerative Disorders
Rosén, C., Zetterberg, H., & Blennow, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-01225-4_20 · Cited by 2
Bombois, S. (2018) · Médecine Nucléaire · doi:10.1016/j.mednuc.2018.03.131 · Cited by 2
Magnetic Tools for Medical Diagnosis
Chieh, J.-J., Liao, S.-H., Wang, L.-M., Huang, K., Yang, H.-C., & Horng, H.-E. (2018) · Springer eBooks · doi:10.1007/978-3-662-56333-5_9 · Cited by 2
Neuropathological Validation of Cerebrospinal Fluid Biomarkers in Neurodegenerative Diseases
Irwin, D. J. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.029876 · Cited by 2
Biomarqueurs du liquide cérébrospinal
Leroy, M., Vaudran, L., Deramecourt, V., Pasquier, F., Chen, Y., Schraen‐Maschke, S., & Lebouvier, T. (2021) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2021.03.014 · Cited by 4
Psychosocial Interventions in Dementia
Kiridoshi, A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.019 · Cited by 2
Stomrud, E. (2009) · Lund University Publications (Lund University) · Cited by 2
Detecting prodromal Alzheimer’s disease with MRI through deep learningPreprint
Feng, X., Provenzano, F. A., Small, S. A., & Initiative, A. D. N. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/813899 · Cited by 2
Predicting Alzheimer’s Disease with Multi-Omic Data: A Systematic ReviewPreprint
Davis, A., Mendoza, W., Leach, D., & Marques, O. (2022) · medRxiv · doi:10.1101/2022.11.25.22282770 · Cited by 2
Neuroimaging and molecular biomarkers of dementia
Polyakova, T., & Араблинский, А. В. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171176216-22 · Cited by 1
Alcohol Misuse in Older People
Rao, R., & CROME, I. B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.009 · Cited by 1
Using Biomarkers for Cognitive Enhancement and Evaluation in Mobile Applications
Γιαννοπούλου, Π., & Vlamos, P. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-31982-2_17 · Cited by 1
Varghese, R., Digholkar, G., Deshpande, A., & Kumar, D. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815136142123010013 · Cited by 1
Sharma, S., Rawat, E., Sharma, P., & Kapoor, D. U. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00231-2 · Cited by 1
Cognitive tests distinguish biomarker-verified early Alzheimer’s disease from other patients
Kiene, F., Notbohm, A., Roheger, M., Duning, T., & Hildebrandt, H. (2026) · BMC Neurology · doi:10.1186/s12883-026-04742-7 · Cited by 1
Delirium Superimposed on Dementia
Eshmawey, M. (2026) · Swiss Archives of Neurology Psychiatry and Psychotherapy · doi:10.3390/sanpp176020008 · Cited by 1
Biomarkers of Neurological Disorders
Jain, K. K. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-272-8_4 · Cited by 1
Exploration clinique des troubles cognitifs chez les sujets âgés
Hugonot-Diener, L., Duron, E., Labouree, F., & Rigaud, A. (2012) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(12)70019-6 · Cited by 1
Alzheimer’S Disease: A Brief Quintessence Medical Management Study
Rani, K., & Bajw, H. S. (2014) · Current Research in Neuroscience · doi:10.3923/crn.2015.20.24 · Cited by 1
Approach to the diagnosis of FTD
Dickerson, B. C. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316091586.011 · Cited by 2
Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
Alzheimer-Associated Pathology in the Extracellular Space
Braak, H., & Tredici, K. D. (2014) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-12679-1_8 · Cited by 1
Relationship Between Cholesterol Metabolism, Apoe and Brain Volumes In Alzheimer‘s Disease
Leoni, V., & Caccia, C. (2011) · Future Neurology · doi:10.2217/fnl.11.38 · Cited by 1
Advances in Alzheimer’s Disease Management
Gauthier, S. G., & Rosa‐Neto, P. (2012) · doi:10.2217/9781780840840 · Cited by 1
Part Two: Extracellular Vesicles as a Risk Factor in Neurodegenerative Diseases
Ceafalan, L. C., Ioghen, O. C., Marta, D. S., Constantin, A. L., Alexandru, N., Nemecz, M., Tanko, G., Filippi, A., Magda, S. L., Bojin, F. M., et al. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86604 · Cited by 1
A “Stress Test” of the 2018 NIA AA Research Criteria for Alzheimer’s Disease
Hildebrandt, H., Kastrup, A., & Eling, P. (2020) · Zeitschrift für Neuropsychologie · doi:10.1024/1016-264x/a000281 · Cited by 1
Impact of the New Conceptual Framework of Alzheimer’s Disease in Imaging Studies
Dubois, B., Villain, N., Jacova, C., & Uspenskaya, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_13 · Cited by 1
Clinical Topics in Old Age Psychiatry
Lilford, P., Adshead, G., & Hughes, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714 · Cited by 1
What Can Person-Centred Care in Dementia Learn from the Recovery Movement?
Hill, L., Roberts, G. A., & Perkins, R. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.018 · Cited by 1
Fluid-Based Biomarkers of Alzheimer’s Disease
Rocha, N. P., Teixeira, A. L., & de Souza, L. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-43356-6_10 · Cited by 1
Anti-inflammatory therapy and cerebrospinal fluid diagnosis in Alzheimer's disease.
de Jong, D. (2010) · Radboud Repository (Radboud University) · Cited by 1
Piersson, A. D., Mohamad, M., Rajab, F., & Suppiah, S. (2020) · medRxiv · doi:10.1101/2020.12.23.20248759 · Cited by 1
Alzheimer's disease-associated biomarkers in delirium and cognitively normal older adults
Idland, A. (2020) · NORA - Norwegian Open Research Archives · Cited by 1
Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's DiseasePreprint
Magnelli, V. (2024) · Preprints.org · doi:10.20944/preprints202401.1595.v1 · Cited by 1
Abazid, M. (2022) · theses.fr (ABES) · doi:10.70675/7ee63a32z36e9z467fzb33fzac28590ebd0f · Cited by 1
Biomarkers of Disorders of the Nervous System
Jain, K. K. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-685-6_7 · Cited by 1
Blutbasierte Mikrozirkulationsmarker bei der Alzheimer-Demenz
Knauer, K. (2010) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.12369
Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints
da Silva, D. L. G. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Potential Blood Biological Markers of Alzheimer's Disease
Metti, A. L. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Balasa, M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Intérêt du dosage des biomarqueurs du LCR dans les démences dégénératives
Bombois, S., Schraen‐Maschke, S., Sablonnière, B., Buée, L., & Pasquier, F. (2011) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2011.09.002
Diagnóstico diferencial etiopatogénico de las demencias: enfermedad de Alzheimer
Sendín, M. A. C., Merino, E. N., & Olazarán, J. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2015.01.006
Diagnosticare la malattia di Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2014) · EMC - Neurologia · doi:10.1016/s1634-7072(14)67223-8
Impact of the IWG/Dubois Criteria for Alzheimer’s Disease in Imaging Studies
Dubois, B., & Uspenskaya, O. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_13
Análisis Multiplex de citoquinas intratecales en pacientes con deterioro cognitivo leve
Borja, E. R., Monge-Argilés, J. A., Soriano-Terol, M. A., & Muñoz‐Ruiz, C. (2011) · Revista del Laboratorio Clínico · doi:10.1016/j.labcli.2011.05.002
Sensibilidad de biomarcadores en el líquido cefalorraquídeo en enfermedades neurodegenerativas
Ribas, G. G., Gómez, I. R., López-Sendón, J. L., Fernandez, M., Bascuñana, M., & de Yébenes, J. G. (2011) · Alzheimer Realidades e investigación en demencia · doi:10.5538/1137-1242.2011.49.26
Génétique des formes autosomiques dominantes de maladie d’Alzheimer
Wallon, D., Campion, D., & Hannequin, D. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0443-9_9
Modeling the Early Identification and Intervention of Alzheimer’s Disease
Michaud, T. L. (2015) · University of Minnesota Digital Conservancy (University of Minnesota)
Cerebrospinalfluid biomarkers of frontotemporal lobar degeneration
Verwey, N. A., Pijnenburg, Y. A. L., & Scheltens, P. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316091586.014
Tsolaki, A. (2015) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-4666-8234-4.ch002
Oh-McGinnis, R., Sigola, L. B., Fuentes, A., Vapenik, J., & Millis, L. (2015) · HAPS Educator · doi:10.21692/haps.2015.023
Diagnostiquer la maladie d'Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2013)
Chorein Deficiency and Alzheimer Disease: An Intriguing, Yet Premature Speculation
Velayos‐Baeza, A., & Danek, A. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000186
Memory decline and Aβ amyloid as markers of neurodegeneration in preclinical Alzheimer's disease
Lim, Y. Y. (2013) · Minerva Access (University of Melbourne)
ERP-based Detection of Brain Pathology in Rat Models for Preclinical Alzheimer's Disease
Nouriziabari, S. B. (2016) · TSpace (University of Toronto)
Engineering antibody therapeutics and cell culture models for neurodegenerative diseases
McHugh, K. P. (2016) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/9ar9-m703
O'Regan, J. (2014) · TSpace (University of Toronto)
Diagnosis of Alzheimer’s disease
Rosa‐Neto, P., Rowley, J., Leuzy, A., Mohades, S., Shin, M., Dauar, M. T., & Gauthier, S. G. (2012) · doi:10.2217/ebo.12.66
Sjödin, S. (2018) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Development and characterization of cell models of tau aggregation
Cavallini, A. (2018) · UCL Discovery (University College London)
Moore, D. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch83
Hort, J., O'Brien, J. T., Gainotti, G., Pirttilä, T., Popescu, B. O., Rektorová, I., Sorbi, S., & Scheltens, P. (2010) · Wiley eBooks · doi:10.1002/9781444328394.ch16
Self-citationBegcevic, I. (2018) · TSpace (University of Toronto)
Neuroimaging and Molecular Biomarkers for Dementia
Polyakova, T., & Араблинский, А. В. (2019) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-019-00747-7
OPTIMIZATION OF PROTEOMIC ANALYSIS METHODS OF COMPLEX BIOLOGICAL MIXTURES
Turton, E. C. (2017) · Digital WPI
Hermann, P. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7519
Designing and preparation of new BACE1 inhibitors for Alzheimer's disease treatment
Manso, M. G. G. A. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Molecular Marker and Therapeutic Regimen for Neurodegenerative Diseases
Dey, S., Rai, N., Shekhar, S., Singh, A. P., & Agnihotri, V. (2019) · Springer eBooks · doi:10.1007/978-981-13-3585-3_2
Mental Health Laws from All UK Jurisdictions
Burrell, C., & Emmett, C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.024
Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer
Cinquanta, L., & Brusca, I. (2019) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.19.00028-8
Bioinformatics Review of the Role of HSV-1 in Alzheimer’s Disease
Reiss, B. T., Eggleston, M. C., Godbole, A. C., Marut, J. A., McCann, C. M., Cottrell, J. A., Chu, T.-C., & Chang, S. L. (2020) · Advances in Alzheimer s Disease · doi:10.4236/aad.2020.93005
Introduction: neuropsychology and the assessment of patients with dementia
Hildebrandt, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821072-7.00001-1
Alzheimer’s disease: neuropathology, neuropsychological differential diagnosis, and treatment
Hildebrandt, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821072-7.00002-3
Management of the predementia stage of Alzheimer’s disease, complicated with hypoactive delirium
Ткачева, О. Н., Cherdak, M. A., & Mkhitaryan, E. A. (2021) · Russian neurological Journal · doi:10.30629/2658-7947-2020-25-6-40-46
McKeever, P. M. (2018) · TSpace (University of Toronto)
Biomarkers of Agitation in Patients with Alzheimer's disease
Ruthirakuhan, M. T. (2019) · TSpace (University of Toronto)
Chemical Isotope Labeling LC-MS for Tissue, Serum and Urine Metabolomics
Wang, X. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3gb1xz8m
Epidemiology and Mental Health in Old Age
Lilford, P., & Hughes, J. C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.004
The Effect of Bilateral Salpingo-Oophorectomy on Cognition in Women Prior to Natural Menopause
Au, A. (2018) · TSpace (University of Toronto)
The Longitudinal Relationships between Biomarkers of Alzheimer’s Disease
Krance, S. H. (2019) · TSpace (University of Toronto)
Diagnosi clinicolaboratoristica della malattia di Alzheimer
Lagarde, J., Olivieri, P., Bottlaender, M., & Sarazin, M. (2021) · EMC - Neurologia · doi:10.1016/s1634-7072(21)45320-1 · Cited by 1
Tau Biomarkers for Long-Term Effects of Neurotrauma: Technology Versus the Null Hypothesis
Castellani, R. J. (2021) · Neuromethods · doi:10.1007/978-1-0716-1712-0_13
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., & Zetterberg, H. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_9
Mental Health in Parkinson’s Disease
Jones, S., Torsney, K., Scourfield, L., Berryman, K., & Henderson, E. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.011
Metadata
- Authors
- Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T.
- Affiliations
- University of Eastern Finland (FI)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-01
- Volume
- 66
- Issue
- 3
- Pages
- 382-9
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2075193321
- Cited by
- 896
- References
- 29
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 78 · 2020: 89 · 2019: 75 · 2018: 60 · 2017: 59 · 2016: 51 · 2015: 65 · 2014: 48 · 2013: 63 · 2012: 41
- FWCI
- 32.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kuopion Yliopistollinen Sairaala
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau, amyloid plaques, neurofibrillary tangles, diagnostic accuracy, lumbar CSF, neurodegeneration, alpha-synuclein, postmortem neuropathology, biomarker ratios, sensitivity and specificity
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cross-Sectional Studies, Dementia, Female, Humans, Immunoassay, Male, Nervous System Diseases, Peptide Fragments, Retrospective Studies, ROC Curve, Logistic Models, Amyloid beta-Peptides, Silver Staining, tau Proteins, Statistics, Nonparametric, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
